JG
CBIO

Jefferies Group’s Crescent Biopharma CBIO Stock Holding History

Jefferies Group’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-313
Closed -$135K – 2711
2019
Q3 		$135K Buy
+313
New +$201K ﹤0.01% 2455
2019
Q2 		– Sell
-596
Closed -$743K – 2650
2019
Q1 		$743K Buy
596
+218
+58% +$250K 0.01% 1419
2018
Q4 		$358K Sell
378
-1,329
-78% -$1.6M ﹤0.01% 1588
2018
Q3 		$2.46M Buy
+1,707
New +$2.58M 0.02% 882
2018
Q1 		– Sell
-539
Closed -$904K – 2420
2017
Q4 		$904K Buy
+539
New +$713K ﹤0.01% 1420

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Jefferies Group's CBIO Position: Q4 2019 in Review

Jefferies Group sold out of Crescent Biopharma (CBIO) in Q4 2019, closing a stake of 313 shares — an estimated $135K sold.

Jefferies Group first reported a position in CBIO in Q4 2017 and held it in 5 quarters. The position peaked at $2.46M in Q3 2018. 78 funds tracked by Wall St. Rank hold CBIO as of Q4 2019.

  • Jefferies Group reported no remaining Crescent Biopharma position as of Q4 2019 after selling out during the quarter.
  • Jefferies Group sold 313 Crescent Biopharma shares in Q4 2019, an estimated $135K.
  • Jefferies Group first reported a position in Crescent Biopharma in Q4 2017 and held it in 5 quarters.
  • Jefferies Group's Crescent Biopharma position peaked at $2.46M in Q3 2018.
  • 78 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2019.

Based on Jefferies Group's 13F filing for Q4 2019, filed 13 Feb 2020.